Greenwich LifeSciences financials
$18.38−1.13%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — |
| Operating income | -$19.4M | -$17.6M | -$9.3M | -$8.0M | -$4.6M | -$1.9M |
| Net income | -$19.4M | -$17.4M | -$8.9M | -$7.8M | -$4.6M | -$1.9M |
| Net margin | — | — | — | — | — | — |
| Diluted EPS | $-1.43 | $-1.34 | $-0.69 | $-0.61 | $-0.35 | $-0.20 |
| EBITDA | -$19.4M | -$17.6M | -$9.3M | -$8.0M | -$4.6M | -$1.9M |
| Operating cash flow | -$9.9M | -$7.3M | -$6.5M | -$6.2M | -$4.3M | -$1.2M |
| Free cash flow | -$9.9M | -$7.3M | -$6.5M | -$6.2M | — | — |
| Diluted shares | 13.5M | 13.0M | 12.8M | 12.9M | 12.9M | 9.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.2M | $4.1M | $7.0M | $13.5M | $27.2M | $28.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $6.2M | $4.1M | $7.0M | $13.5M | $27.2M | $28.7M |
| Total liabilities | $5.8M | $3.2M | $294.4K | $262.9K | $385.2K | $1.0M |
| Shareholders' equity | $353.2K | $908.6K | $6.7M | $13.2M | $26.8M | $27.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology